Omniscient secured a $27.2M Series D to accelerate the commercialization of its AI-enabled brain-mapping technology. The company builds software that maps functional brain networks from imaging data, positioned as a tool layer for neurosurgical planning and neurological care. The round signals investor appetite for the analytics and infrastructure side of neuroimaging, where value accrues to interpretation rather than acquisition. The funding also coincides with a new CPT code, signalling work on the reimbursement layer.